Bio-Techne (TECH) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TECH Bio-Techne

Watchlist

66.860
-0.710-1.05%

Close Nov 18 16:00 ET

10.62BMarket Cap70.38P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Kevin Travers16:21 ET
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Kevin Travers11:21 ET
Bio-Techne, ALZpath Announce Strategic Partnership
TipRanksNov 18 07:11 ET
Express News | Bio-Techne Corp - Partnership to Provide Simple Plex Human Phospho-Tau (T217) Alzpath Assay
ReutersNov 18 07:00 ET
Express News | Bio-Techne and Alzpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
ReutersNov 18 07:00 ET
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
PR NewswireNov 18 07:00 ET

Comments

The Thinker

Oct 30 19:36

U.S. Markets Slide as Tech Wobbles and Treasury Yields Surge

Click Here: TYNKR LAB™
The U.S. stock markets closed in negative territory as tech shares faced selling pressure, and rising Treasury yields added to the cautious sentiment. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.22%, $S&P 500 Index (.SPX.US)$ lost 0.33%, and $Nasdaq Composite Index (.IXIC.US)$ declined by 0.49%. This downturn highlights investor apprehension driven by economic concerns and mixed corporate earnings results, pa...

Magnificent Earnings Week: What was your fave?

Stock_Drift

Sep 17 06:04

$Bio-Techne (TECH.US)$

Trytosaveabit

May 22 06:21

Update

$Regulus Therapeutics (RGLS.US)$ $Bio-Techne (TECH.US)$ Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Moomoo AI

Dec 28, 2023 05:17

Despite Bio-Techne's high P/E ratio, the lower forecast growth potentially overvalues it. Investors may risk a share price decline due to weak earnings outlook, posing a risk for those holding onto shares.